Cargando…

Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study

BACKGROUND: A majority of patients undergoing curative intent surgery for pancreatic ductal adenocarcinoma (PDAC) will unfortunately develop recurrent disease. Treatment outcomes for patients with metastatic disease remain suboptimal. In this study, we evaluated clinical outcomes of patients with re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miotke, Laura, Nevala-Plagemann, Christopher, Ying, Jian, Florou, Vaia, Haaland, Benjamin, Garrido-Laguna, Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554966/ https://www.ncbi.nlm.nih.gov/pubmed/36224524 http://dx.doi.org/10.1186/s12885-022-10130-4

Ejemplares similares

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2019)

Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
por: Florou, Vaia, et al.
Publicado: (2021)

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2018)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Desmoid Fibromatosis Mimicking Metastatic Recurrence After Pancreatectomy for Pancreatic Adenocarcinoma
por: Navin, Patrick, et al.
Publicado: (2018)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
por: Zeng, Fujuan, et al.
Publicado: (2021)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion
por: Nevala-Plagemann, C., et al.
Publicado: (2019)

Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project
por: Shimoyama, Rai, et al.
Publicado: (2023)

Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data
por: Barzi, Afsaneh, et al.
Publicado: (2023)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
por: Taieb, Julien, et al.
Publicado: (2023)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2023)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
por: Bengtsson, Axel, et al.
Publicado: (2020)

Real World Data for Pancreatic Adenocarcinoma from a Population-Based Study in France
por: Badic, Bogdan, et al.
Publicado: (2023)

Metastatic Pancreatic Adenocarcinoma During Pregnancy
por: Davis, Jessica, et al.
Publicado: (2016)

Metastatic Pancreatic Adenocarcinoma to Umbilical Skin
por: Aghighi, Maryam, et al.
Publicado: (2022)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
por: Steenbruggen, Tessa G, et al.
Publicado: (2021)

Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
por: McKenzie, Hayley S., et al.
Publicado: (2020)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
por: Yoo, Changhoon, et al.
Publicado: (2019)

Emerging mechanisms of immunotherapy resistance in sarcomas
por: Florou, Vaia, et al.
Publicado: (2022)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer
por: Wallis, Christopher J D, et al.
Publicado: (2021)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Real‐world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma
por: Grogan, Alexander, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kj0biikdqdo7qd4784qft3arhs